Sustainability
As a company formed of two sustainability leaders, we’re determined to keep growing our positive impact – for the good of people, climate, and nature.
Lactéol® is a well-established, internationally recognized postbiotic solution, specifically designed to manage digestive disorders. It has a unique postbiotic composition, with Lactobacillus LB and its metabolite-rich spent culture medium. This combination maximizes anti-diarrheal activity with several benefits:
Contact us and learn more about how Lactéol® can help you create digestive solutions that help consumers thrive.
Humiome® Post LB is a safe, stable and easy-to-use postbiotic ingredient comprising a unique combination of two proprietary Lactobacillus strains, metabolites, and fermented culture medium that offers benefits including:
Suitable for supplements or functional food and beverages in human health applications, Humiome® Post LB can help you unlock new opportunities for postbiotic innovation.
Safe, efficient, and easy-to-use, LBiotix™ is a new postbiotic ingredient developed specifically for animal health, based on our unique microbiome technology platform. LBiotix™ is a pioneering postbiotic solution specifically designed to support gut health and immunity of production animals. A number of studies have confirmed the positive impact of LBiotix™ on:
Contact us and learn more about how LBiotix™ can help you create digestive solutions that help consumers thrive.
We’re your end-to-end partner for bringing next generation postbiotic solutions to market. Get in touch with our team at the links below and discover how we can help you bring progress to life.
Do you have questions about Lactéol®? Our team is on hand with the answers you’re looking for. Contact our team to learn more.
Want to know more about how Humiome® Post LB can help unleash the power of postbiotics in your next innovation? Get in touch.
Learn more about how our LBiotix™ ingredient for feed solutions can help you support animal health – contact our team today.
References:
1-Xiao SD, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-60
2-Tarrerias et al. The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig Dis. 2011;29(6):588–591.
3-Oral Probiotics Reduce Incidence of Necrotizing Enterocolitis and Sepsis in Neonates with Hypoxic Ischemic Encephalopathy.
Elfrargy et al. 2014 Journal of American Science
4-Tarrerias et al. The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig Dis. 2011;29(6):588–591.
5- Liévin-Le Moal V, et al. An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea. Pediatrics. 2007;120(4):e795-803.
6-Multicenter, Randomized, Controlled Trial of Heat-Killed Lactobacillus acidophilus LB in Patients with Chronic Diarrhea.
Xiao et al. 2003. Advances in Therapy
7-Salazar-Lindo E. et al. Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children. JPGN. 2007; 44:571-576
As a company formed of two sustainability leaders, we’re determined to keep growing our positive impact – for the good of people, climate, and nature.
With over a century of scientific leadership under our belts, we keep pushing the boundaries of what’s possible to improve billions of lives.
If you wake up hungry for progress, we’d love to have you on board at dsm-firmenich. Help make a real difference and bring progress to life.